Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thymidine monophosphate kinase (TMPKmt) is an essential enzyme in Mycobacterium tuberculosis, encoded by the tmk gene (Rv3247c)[1][6]. It catalyzes the reversible phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), a critical step in the de novo and salvage pathways of DNA synthesis and repair[1][5][6]. This enzyme is structurally unique to the bacterium, making it a promising therapeutic target for tuberculosis drug development[2][3]. Inhibiting TMPKmt disrupts nucleotide synthesis, compromising mycobacterial DNA replication and survival, particularly important for non-replicating (dormant) forms of the bacterium[1][2]. Despite promising inhibitors identified in research, challenges remain with intracellular drug delivery and selective inhibition versus the human homologs[2][3].
Inhibition of TMPKmt depletes dTDP and dTTP pools, thereby blocking DNA synthesis and cell division in M. tuberculosis[1][2][3]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymidine monophosphate kinase (Mycobacterium tuberculosis) (TMPKmt).